PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that academic collaborators and scientists from the company will present data on the Dynamic PolyConjugate™ (DPC) siRNA delivery system, the ARC-520 hepatitis B drug candidate, and the Homing Peptide™ platform at upcoming scientific conferences.
"The pace of innovation by our scientists in Madison over the last year has been impressive," said Dr. Christopher Anzalone, President and Chief Executive Officer. "We have made important progress, particularly with new subcutaneous and tumor-targeted DPCs and our ARC-520 HBV clinical program, which we are eager to discuss at conferences and through peer-reviewed publications."
Scheduled conference presentations in February are as follows:
The Sixteenth International Symposium on Recent Advances in Drug Delivery Systems - Salt Lake City, Utah, February 3-6, 2013
A poster titled, “Hepatocyte-Targeted Melittin-Like Peptide (MLP) as A New Endosomolytic Excipient for Liver Delivery of Therapeutic siRNAs: Biodistribution and Elimination,” will be presented by Vladimir S. Trubetskoy, PhD, Senior Scientist;
A poster titled, “Novel Maleic Anhydride Based Polymer Masking Reagents for Targeted siRNA Delivery with Dynamic Polyconjugates,” will be presented by Andrei Blohkin, PhD, Senior Scientist;
An oral presentation titled, “Ligand-directed Therapy and Molecular Imaging Based on in vivo Phage Display Technology,” will be presented by Renata Pasqualini, PhD, Helen Buchanan & Stanley Seeger Professor of Medicine and Experimental Diagnostic Imaging, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX;
An oral presentation titled, “Ligand-directed Targeting and Imaging in Translational Medicine,” will be presented by Wadih Arap, MD, PhD, Stringer Professor of Medicine and Experimental Diagnostic Imaging, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX;
AsiaTIDES: Oligonucleotide and Peptide Research, Technology and Product Development - Tokyo, Japan, February 26-28, 2013
An oral presentation titled, “Dynamic Polyconjugate (DPC) Technology for Targeted siRNA Delivery,” will be presented by David Lewis, PhD, Vice President, Biology and Madison Site Head.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus. The company is leveraging its platform technologies to design and develop peptide-drug conjugates (PDCs) that specifically home to cell types of interest while sparing off-target tissues, create targeted drugs based on the gene silencing RNA interference (RNAi) mechanism, and work with partners to create improved versions of traditional small molecule drugs.
For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to email@example.com
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.